ReflectivAI

Request Demo

← All insights

· 4 min read · Tony Abdelmalak

Shrinking HCP Access Demands Real-Time Training Precision: From 60% to 45% Availability

Field rep access to HCPs has fallen to pre-pandemic levels: only 45% are accessible to biopharmas, down from 60% eighteen months earlier, and half of those restrict engagement to digital channels.

The Access Window Just Got Smaller

Everyone in commercial leadership is talking about digital engagement. Very few are talking about the math underneath it.

Access to HCPs isn't stable. It's shrinking, fast.

According to Marzipan, citing Veeva Pulse field data, "the share of U.S. HCPs accessible to field reps fell from 60% to 45% in a single year, and half of the HCPs who remain accessible limit their engagement to three or fewer companies." That's not a slow drift. That's a cliff.

Pharmaphorum confirms the same pattern globally: "Today, only 45% of HCPs globally are accessible to biopharmas compared to 60% eighteen months ago, with half restricting engagement to three or fewer companies."

Two different analyses. Same number. Same direction.

How We Got Here

The 60% figure wasn't always the baseline. It was a peak.

MM+M reported that "the increasing number of clinicians willing to meet virtually has driven the rate of rep-friendly physicians to a record high of 60% in the U.S., according to a recent report released by Veeva," a rebound from lows near 20% during the pandemic. That peak felt like progress.

It wasn't permanent.

Access opened during a crisis. Then it closed again. Fast.

Pharmaphorum points to structural reasons: "In the UK, HCP access now sits at 25% due to several underlying factors, including increased market consolidation, health system restrictions, growing patient loads, and the increasing diversity and complexity of modern medicine."

None of that reverses on its own. Consolidation doesn't undo itself. Patient loads don't shrink because a rep wants a meeting.

It Gets Worse by Specialty and Geography

Averages hide the real story.

Geography compounds access constraints. The UK sits at 25% due to market consolidation, health system restrictions, and growing patient loads. That's the tightest access in Europe. And even where a meeting happens, it's rarely open-ended.

MM+M found that more than half of accessible HCPs meet with three or fewer companies, and willingness varies significantly by specialty.

Fewer doors. Shorter list of who gets through them.

Fewer Reps, Higher Stakes

Here's what commercial leaders underestimate: it isn't just that meetings are scarcer.

It's that each one now carries more weight.

If an HCP only sees three companies this year, every conversation your rep has is doing the work of five. There's no room for a generic pitch, a mistimed objection response, or a rep who hasn't fully absorbed the message architecture.

That isn't a call volume problem. It's a precision problem.

And precision isn't something classroom training builds well under time pressure. Hyperbound notes that ramp time for new sales reps often exceeds nine months. Nine months to full readiness inside a market where the HCP relationship window may already be closing.

That gap—the space between when a rep starts talking to physicians and when they're actually good at it—used to be an inefficiency. Now it's a liability.

What This Means for Training

Most commercial training was built for a world with more room for error. More calls, more chances, more time to sharpen a rep's instincts on the job.

That world isn't coming back at scale.

If half the accessible HCPs are limiting themselves to three companies, then every single interaction is closer to a final exam than a practice round. Reps need to walk in ready to notice what's actually happening in the room, interpret it correctly, and respond with judgment, not a script.

That's the argument behind Signal Intelligence. Making the judgment inside a high-stakes conversation visible and measurable before the rep is in front of a physician who may never give them a second meeting.

Not by replacing reps or automating the conversation. By giving commercial teams a way to see where judgment is strong and where it isn't, human-led and governed, before the access window closes.

The Real Question

Access isn't coming back to 2021 levels. Every data point points the other way.

So the question for commercial leaders isn't how to get more meetings. It's whether your reps are ready for the ones they still have.

Sources